Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 27, 2015, Pages 8427-8432

  Spiess, Katja ^a,b   Jeppesen, Mads G ^a   Malmgaard Clausen, Mikkel ^a   Krzywkowski, Karen ^a   Dulal, Kalpana ^c   Cheng, Tong ^d   Hjortø, Gertrud M ^b   Larsen, Olav ^b   Burg, John S ^e   Jarvis, Michael A ^f   Garcia, K Christopher ^e   Zhu, Hua ^c   Kledal, Thomas N ^a,g   Rosenkilde, Mette M ^b  

^a INAGEN ApS   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d XIAMEN UNIVERSITY   (China)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PLYMOUTH   (United Kingdom)

^g TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

7TM GPCR; Antiviral drug; Chemokine; HCMV; Protein engineering

Indexed keywords

ANTIVIRUS AGENT; BETA CHEMOKINE; CHEMOKINE RECEPTOR CX3CR1; CX3C CHEMOKINE; CX3CL1 CHEMOKINE PSEUDOMONAS EXOTOXIN A FUSION TOXIN PROTEIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR US28; HYBRID PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MUCIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; BACTERIAL PROTEIN; CHEMOKINE RECEPTOR; FRACTALKINE; PROTEIN BINDING; PSEUDOMONAS EXOPROTEIN A PROTEIN, PSEUDOMONAS AERUGINOSA; US28 RECEPTOR, CYTOMEGALOVIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL KILLING; CELL MIGRATION; CELL SURFACE; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SINGLE DRUG DOSE; VIRUS REPLICATION; VIRUS VIRULENCE; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; CYTOLOGY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOSE RESPONSE; DRUG EFFECTS; FIBROBLAST; GENETICS; HEK293 CELL LINE; HOST PATHOGEN INTERACTION; LUNG; METABOLISM; PHYSIOLOGY; TIME FACTOR; VIROLOGY;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; PSEUDOMONAS EXOTOXIN;

BACTERIAL PROTEINS; CELL LINE; CELL SURVIVAL; CHEMOKINE CX3CL1; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FIBROBLASTS; HEK293 CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; LUNG; PROTEIN BINDING; RECEPTORS, CHEMOKINE; RECOMBINANT FUSION PROTEINS; TIME FACTORS; VIRAL PROTEINS;

EID: 84936818794     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1509392112     Document Type: Article

References (47)

1. Lewis Phillips GD, et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68(22):9280-9290.
2. Seetharam S, Chaudhary VK, FitzGerald D, Pastan I (1991) Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biol Chem 266(26):17376-17381.
3. Kreitman RJ (2013) Hairy cell leukemia-new genes, new targets. Curr Hematol Malig Rep 8(3):184-195.
4. Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I (2014) Immunotoxins for leukemia. Blood 123(16):2470-2477.
5. Choudhary S, Mathew M, Verma RS (2011) Therapeutic potential of anticancer immunotoxins. Drug Discov Today 16(11-12):495-503.
6. Petersdorf SH, et al. (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121(24):4854-4860.
7. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5(2):147-159.
8. Antignani A, Fitzgerald D (2013) Immunotoxins: The role of the toxin. Toxins (Basel) 5(8):1486-1502.
9. Liu XF, FitzGerald DJ, Pastan I (2013) The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin. Cancer Res 73(7):2281-2288.
10. Du X, Beers R, Fitzgerald DJ, Pastan I (2008) Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 68(15):6300-6305.
11. Mocarski ES, Shenk T, Pass RF (2007) Cytomegaloviruses in Field's Virology, ed Howley PM (Lippincott, Williams & Wilkins, Philadelphia), 5th Ed, pp 2701-2772.
12. Biron KK (2006) Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71(2-3): 154-163.
13. St Clair MH, Furman PA, Lubbers CM, Elion GB (1980) Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir. Antimicrob Agents Chemother 18(5):741-745.
14. Singh N (2006) Cytomegalovirus infection in solid organ transplant recipients: New challenges and their implications for preventive strategies. J Clin Virol 35(4):474-477.
15. Sia IG, Patel R (2000) New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 13(1): 83-121.
16. Härter G, Michel D (2012) Antiviral treatment of cytomegalovirus infection: An update. Expert Opin Pharmacother 13(5):623-627.
17. Jacobsen T, Sifontis N (2010) Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm 67(17): 1417-1425.
18. Reddy AJ, Zaas AK, Hanson KE, Palmer SM (2007) A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: Treatment and outcome. J Heart Lung Transplant 26(12):1286-1292.
19. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M (2000) Emergence of ganciclovirresistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356(9230):645-649.
20. Rosenkilde MM, Kledal TN (2006) Targeting herpesvirus reliance of the chemokine system. Curr Drug Targets 7(1):103-118.
21. Allen SJ, Crown SE, Handel TM (2007) Chemokine: Receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787-820.
22. Thiele S, Rosenkilde MM (2014) Interaction of chemokines with their receptors-from initial chemokine binding to receptor activating steps. Curr Med Chem 21(31): 3594-3614.
23. Burg JS, et al. (2015) Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor. Science 347(6226):1113-1117.
24. Casarosa P, et al. (2005) CC and CX3C chemokines differentially interact with the N terminus of the human cytomegalovirus-encoded US28 receptor. J Biol Chem 280(5): 3275-3285.
25. Kledal TN, Rosenkilde MM, Schwartz TW (1998) Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28. FEBS Lett 441(2):209-214.
26. Bazan JF, et al. (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617):640-644.
27. Fraile-Ramos A, et al. (2001) The human cytomegalovirus US28 protein is located in endocytic vesicles and undergoes constitutive endocytosis and recycling. Mol Biol Cell 12(6):1737-1749.
28. Fraile-Ramos A, Kohout TA, Waldhoer M, Marsh M (2003) Endocytosis of the viral chemokine receptor US28 does not require beta-arrestins but is dependent on the clathrin-mediated pathway. Traffic 4(4):243-253.
29. Weidle UH, et al. (2014) Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genomics Proteomics 11(1):25-38.
30. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6(7):559-565.
31. Ishida Y, Gao J-L, Murphy PM (2008) Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J Immunol 180(1):569-579.
32. Dulal K, Zhang Z, Zhu H (2009) Development of a gene capture method to rescue a large deletion mutant of human cytomegalovirus. J Virol Methods 157(2):180-187.
33. Mocarski ES, Bonyhadi M, Salimi S, McCune JM, Kaneshima H (1993) Human cytomegalovirus in a SCID-hu mouse: Thymic epithelial cells are prominent targets of viral replication. Proc Natl Acad Sci USA 90(1):104-108.
34. Gönczöl E, Ianacone J, Furlini G, Ho W, Plotkin SA (1989) Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-passage strain. J Infect Dis 159(5):851-859.
35. Barrett L, Walmsley S (2012) CMV retinopathy in the antiretroviral therapy era: Prevention, diagnosis, and management. Curr Infect Dis Rep 14(4):435-444.
36. Billstrom MA, Lehman LA, Scott Worthen G (1999) Depletion of extracellular RANTES during human cytomegalovirus infection of endothelial cells. Am J Respir Cell Mol Biol 21(2):163-167.
37. Bodaghi B, et al. (1998) Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: Withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J Exp Med 188(5):855-866.
38. Brown JM, Kaneshima H, Mocarski ES (1995) Dramatic interstrain differences in the replication of human cytomegalovirus in SCID-hu mice. J Infect Dis 171(6):1599-1603.
39. Togashi J, et al. (2011) Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: A randomized trial. Biosci Trends 5(5):217-222.
40. Guo H, Kaiser WJ, Mocarski ES (2015) Manipulation of apoptosis and necroptosis signaling by herpesviruses. Med Microbiol Immunol (Berl) 204(3):439-448.
41. Ménard C, et al. (2003) Role of murine cytomegalovirus US22 gene family members in replication in macrophages. J Virol 77(10):5557-5570.
42. Kaminetzky D, Hymes KB (2008) Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics 2(4):717-724.
43. Rosada RS, et al. (2010) Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A. PLoS ONE 5(1):e8721.
44. Hjortø GM, Hansen M, Larsen NB, Kledal TN (2009) Generating substrate bound functional chemokine gradients in vitro. Biomaterials 30(29):5305-5311.
45. Thiele S, et al. (2011) Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. J Biol Chem 286(43):37543-37554.
46. Voigt S, et al. (2005) Fatal reactivation of postnatal cytomegalovirus infection with rapid emergence of ganciclovir resistance in an infant after allogeneic stem cell transplantation. J Clin Microbiol 43(7):3551-3554.
47. Committee on Care and Use of Laboratory Animals (1996) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.